Or, why 2016 might look a little different than 2015 for pharmaceutical marketers.
2015 U.S. trends in aggregate spend, disclosure, and transparency
Biotech, Centers for Medicare & Medicaid Services, Centers for Medicare and Medicaid Services (CMS), CMS, Europe, European Federation of Pharmaceutical Industries and Associations (EFPIA), February 2016, Healthcare Physicians, Issue Archives, Medical Devices, Physicians, Surveys, Trends, U.S. Sunshine LawWhat are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
2016 Annual Report: Top 10 Pipelines
"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemiaThe pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
Special Feature — Sales-Force Effectiveness: The Sweet 16
Accountable Care Organizations (ACOs), Electronic Health Records, February 2016, Healthcare Physicians, Incentives, Integrated Delivery Networks (IDNs), Issue Archives, Marketing & Advertising, Patients, Physicians, Sales & Marketing, Sales Reps, Sales-Force Effectiveness, TrendsIndustry experts tell Med Ad News about 16 trends that they believe will affect sales-force strategies in the immediate future.
The Medical Advertising Hall of Fame honored C. Marshall Paul and Scott Cotherman as 2016 inductees; Ken Begasse Sr. was the Lifetime Achievement Award recipient.
The CHC’s mission is to promote and protect the benefit, for society and individual patient care, of the free flow of healthcare information.
At Intouch we hold a number of truths to be self-evident, but perhaps the most self-evident of the lot is this: that digital sales aids only work if sales reps actually use them. Seems pretty obvious, right? The trouble is, not everyone does use them.
Access to information at the moment of decision making is continuously altering the consumer decision pathway and the ubiquity of personal technology is accelerating these changes.
Ever had one of those revelatory moments when someone, or something, questions the logic behind your established, “tried and trusted” approach to performing a particular function or solving a certain set of problems – “Why are we still doing it this way?” – and the only honest answer you can think of is, “Because that’s how we’ve always done it?”